Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Results of Operations and Financial Condition
25 Apr 24
8-K
Other Events
9 Apr 24
8-K
Regulation FD Disclosure
5 Apr 24
8-K/A
Financial Statements and Exhibits
1 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
1 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Mar 24
8-K
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
20 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
5 Mar 24
8-K
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple
5 Feb 24
8-K/A
Departure of Directors or Certain Officers
2 Feb 24
8-K
2seventy bio Announces New Strategic Path Forward
30 Jan 24
S-8
Registration of securities for employees
5 Jan 24
8-K
Regulation FD Disclosure
12 Dec 23
UPLOAD
Letter from SEC
4 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
UPLOAD
Letter from SEC
22 Nov 23
8-K
Other Events
20 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
14 Nov 23
8-K
Results of Operations and Financial Condition
26 Oct 23
8-K
Unleash Time 2seventy bio company presentation September 2023
13 Sep 23
8-K
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
12 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
14 Aug 23
8-K
Results of Operations and Financial Condition
27 Jul 23
8-K
Unleash Time 2seventy bio company presentation June 2023
14 Jun 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
8-K
Regulation FD Disclosure
19 May 23
8-K
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
17 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
Latest ownership filings
4
Jessica Snow
3 Apr 24
4
Victoria Eatwell
3 Apr 24
4
William D Baird III
3 Apr 24
3
Victoria Eatwell
3 Apr 24
3
Jessica Snow
3 Apr 24
4
Eli Casdin
28 Mar 24
4
Eli Casdin
25 Mar 24
3
Eli Casdin
25 Mar 24
4
Charles W. Newton
25 Mar 24
3
Charles W. Newton
25 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
MORGAN STANLEY
12 Feb 24
SC 13G
GOLDMAN SACHS GROUP INC
8 Feb 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
William D Baird III
9 Jan 24
4
Philip D Gregory
9 Jan 24
4
Nick Leschly
9 Jan 24
4
Nick Leschly
5 Jan 24
4
Philip D Gregory
5 Jan 24
4
William D Baird III
5 Jan 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 Nov 23
SC 13G/A
STATE STREET CORP
10 Oct 23
SC 13G
Kynam Capital Management, LP
6 Sep 23
4
Nick Leschly
24 Aug 23
4
Philip D Gregory
24 Aug 23
4
William D Baird III
24 Aug 23
4
Yue Tang
16 Aug 23
3
Yue Tang
16 Aug 23
4
Change in insider ownership
14 Aug 23
3
Initial statement of insider ownership
14 Aug 23
4
Nick Leschly
7 Aug 23
4
Philip D Gregory
7 Aug 23
4
William D Baird III
7 Aug 23
4
Ramy Ibrahim
15 Jun 23
4
Denice Torres
15 Jun 23
4
Marcela V. Maus
15 Jun 23